[{"id":"a3ff3bf1-6fbc-4e00-b8e0-454d7fb78cce","acronym":"","url":"https://clinicaltrials.gov/study/NCT05687136","created_at":"2023-01-18T15:59:53.342Z","updated_at":"2025-02-25T13:41:23.007Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors","source_id_and_acronym":"NCT05687136","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ATM • ARID1A • CCNE1 • PBRM1 • FBXW7 • ATRX • ARID1B • ARID2 • SMARCA2 • SS18","pipe":" | ","alterations":" ATM mutation • ARID1A mutation","tags":["ATM • ARID1A • CCNE1 • PBRM1 • FBXW7 • ATRX • ARID1B • ARID2 • SMARCA2 • SS18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e peposertib (M3814) • tuvusertib (M1774)"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 06/07/2024","start_date":" 06/07/2024","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2025-02-21"},{"id":"a6c5fc58-82ce-40df-9b35-73d1f5f08ae5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05864742","created_at":"2023-05-18T14:05:05.741Z","updated_at":"2024-07-02T16:35:04.334Z","phase":"Phase 2","brief_title":"Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma","source_id_and_acronym":"NCT05864742","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" BCL2 • BCL2L2 • SMARCA2","pipe":"","alterations":" ","tags":["BCL2 • BCL2L2 • SMARCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • navitoclax (ABT 263)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/07/2023","start_date":" 09/07/2023","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2024-05-10"},{"id":"a12b006f-dc84-4bc8-80cc-7523ed0f98b1","acronym":"ENIGMA","url":"https://clinicaltrials.gov/study/NCT05205200","created_at":"2022-01-25T16:54:16.056Z","updated_at":"2024-07-02T16:35:20.272Z","phase":"Phase 2","brief_title":"Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02","source_id_and_acronym":"NCT05205200 - ENIGMA","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR • SMARCA2","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR • SMARCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • fulvestrant • AiRuiKang (dalpiciclib) • AiRuiLi (adebrelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 338","initiation":"Initiation: 06/06/2022","start_date":" 06/06/2022","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-02-08"}]